It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Novavax program of clinical trials evaluating the safety and efficacy of NVX-CoV2373 across the US, South Africa and the UK. Please find Part 1 of this interview available here.
To access more COVID-19 content, please visit our COVID-19 Hub.
Questions:
- What were the findings of the Phase 3 trials in terms of prevention of mild, moderate and severe COVID-19 from variant strains currently in circulation?
Disclosures: Paul Heath has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
